# A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

> **NCT01164007** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 40 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01164007
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-30
- **Primary completion:** 2012-05-31
- **Final completion:** 2012-05-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164007, "A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01164007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*